Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 12/20 | 0.74 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.74 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.74 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.74 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.74 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.61 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1462933 | 0.90 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1463969 | 0.85 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1463449 | 0.82 | CHRNB2 (0.64) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1463817 | 0.81 | CHRNA4 (0.72) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1711364 | 0.81 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1463764 | 0.81 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1711487 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1711593 | 0.81 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1463829 | 0.79 | CHRNB2 (0.70) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 | |
| SCHEMBL1464128 | 0.78 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | claimed |
| EP-2257549-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | Targacept Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2257549-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | Targacept Inc. (US) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111550-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOAL KANES | TARGACEPT, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071180-A1 | SUB-TYPE SELECTIVE AMIDES OF DIAZABICYCLOALKANES | CHRNA7, CHRNA2, CHRNA5 | CHRNB2 4/4885CHRNA4 6/4885CHRNA3 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.